2024-11-06 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis

**Company Overview:** Intuitive Surgical Inc. is a leading provider of robotic-assisted surgical systems and instruments, revolutionizing minimally invasive surgery.

**Performance Analysis:**

**1. Outperformance vs. S&P 500 (VOO):**

* **Cumulative Return:** ISRG has outperformed the S&P 500 significantly, with a cumulative return of 371.13% compared to 134.06% for VOO. 
* **Relative Outperformance:** ISRG is currently 237.07% ahead of VOO, placing it within the 81.67th percentile of historical relative outperformance (based on the provided data).
* **Alpha and Beta Analysis:** ISRG exhibits consistently strong Alpha values, demonstrating its ability to outperform the market, while its Beta remains relatively stable around 1.2-1.4, suggesting moderate volatility compared to the overall market.

**2. Recent Price Action:**

* **Closing Price:** 515.17
* **5-day Moving Average:** 509.31
* **20-day Moving Average:** 502.11
* **60-day Moving Average:** 489.66
* **Analysis:** ISRG's price is currently trading above all three moving averages, suggesting an upward trend. The 5-day and 20-day moving averages are converging, indicating potential for continued upward momentum.

**3. Technical Indicators:**

* **RSI:** 71.49 -  This indicates that ISRG is currently in overbought territory, suggesting potential for a short-term correction.
* **PPO:** -0.02 - This indicates a slight bearish divergence between the short-term and long-term momentum, but it's not particularly alarming at this point.
* **Delta_Previous_Relative_Divergence:** 8.06 (+) -  This signifies that ISRG is experiencing a positive divergence in its relative performance, potentially indicating continued strength in the short term.
* **Expected Return:** 12.57% -  This suggests that ISRG is expected to generate a higher return than the S&P 500 over the long term (2+ years) through a long-term investment strategy.

**4. Recent Earnings and Outlook:**

* **Earnings:** ISRG has consistently demonstrated strong earnings growth, exceeding revenue expectations and maintaining a steady profit margin. 
* **Analysis:** While there is a slight decrease in EPS from Q2 2024 to Q3 2024, it's important to note that revenue is still increasing, suggesting the company is managing costs effectively.
* **Most Recent Earnings:**  ISRG reported Q3 2024 earnings on October 18th, exceeding analysts' expectations with EPS of $1.59, while revenue came in at $2.04 Billion. 

**5. Financial Information:**

* **Revenue and Profitability:** ISRG exhibits consistently high revenue growth and consistently strong profit margins, indicative of its strong market position and operational efficiency. 
* **Capital and Profitability:**  ISRG demonstrates a robust equity position and relatively stable ROE, showcasing financial strength and a consistent track record of profitability.

**6. News and Recent Issues:**

* **Recent Earnings Release:** The most recent earnings announcement on October 18th, 2024, was met with positive market reactions due to exceeding earnings expectations.
* **Market Outlook:**  Analysts are generally optimistic about ISRG's future prospects, citing its strong market position, technological advancements, and continued growth in the minimally invasive surgery market. 
* **Analyst Opinions:**  According to FINBOLD, the majority of analysts maintain a "buy" rating on ISRG, with a consensus price target of $550.

**7.  Overall Analysis:**

ISRG continues to demonstrate impressive performance, exceeding both earnings expectations and S&P 500 returns. The company exhibits strong financial health, solid growth trajectory, and positive market sentiment. While the recent price action indicates a potential short-term correction due to overbought conditions, ISRG's long-term prospects remain robust, with the expected return suggesting continued outperformance against the broader market.  However, it's essential to monitor ISRG's performance closely, especially for any potential signs of slowing growth or market share loss. 

**8. Recommendation:**

Investors seeking long-term growth with potential for high returns should consider ISRG as a promising addition to their portfolios. It's important to note that the stock's current overbought status may warrant a wait-and-see approach for potential pullbacks.  However, the long-term outlook remains positive, and ISRG's continued growth potential is worth considering for long-term investment. 
